Table 1 VHA Dialysis Dashboard Clinical Performance Measures

Monthly measurement of delivered hemodialysis dose

CMS^a

process

% patients w/ documented monthly adequacy measurements (spKt/V, URR)

Minimum delivered Hemodialysis dose

NQF^b

Intermediate outcome

% patients on thrice-weekly hemodialysis whose average spKt/V > = 1.2 OR URR > 0.67

Minimizing use of catheters as chronic dialysis access

NQF

Intermediate outcome

% patients during the last HD treatment of month with a catheter continuously for 90 days or longer prior

Maximizing placement of arterial venous fistula (AVF)

NQF

Intermediate outcome

% patients during the last HD treatment of month using an autogenous AVF with two needles

Assessment of Iron Stores

CMS

process

% patients for whom serum ferritin and transferrin saturation percentage (TSAT) are measured simultaneously at least once during the rolling three-month study period.

Anemia Management: Hgb > 12

CMS

Intermediate outcome

% patients w/ hemoglobin value > 12.0 and on ESA

Measurement of serum phosphorus concentration

NQF

process

% patients with phosphorus measured at least once within month

Measurement of serum calcium concentration

CMS

process

% patients with calcium measured at least once within month

Proportion of patients with hypercalcemia

NQF

Intermediate outcome

% patients with 3-month rolling average of total uncorrected serum calcium > 10.2 mg/dL

Bloodstream infection measure

NQF

outcome

Number of outpatients with positive blood cultures per 100 hemodialysis patient-months

Influenza immunization

KCP^c

process

% patients during the time from September 1 to March 31 who either received, were offered and declined, or were determined to have a medical contraindication to the influenza vaccine